About Inquest Biopharm Private Limited
Data last updated:
Inquest Biopharm Private Limited is a private limited company based in Ahmedabad, Gujarat, India. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 14 September 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U73100GJ2017PTC099096. Its GSTIN is 24AAECI6298M1ZZ (Gujarat).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Kapil Ashvinbhai Pandya and Minakshi Kapil Pandya.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ahmedabad, Gujarat.
As per the financials filed for FY 2024, the company reported a revenue of ₹77.08 Lakh, a decline of 33% compared to the previous year. For the same year it recorded a net profit of ₹7.43 Lakh (net margin 9.6%) and EBITDA of ₹11.9 Lakh (EBITDA margin 15.4%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years and 4% over five years.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website inquestbp.com.
Company details
Contact details
Inquest Biopharm Private Limited's registered office is in Ahmedabad, Gujarat. Its website is inquestbp.com. Its e-mail address is in the company report.
- Email
- Website
- Registered AddressE – 512 Ganesh Glory – 11, Near Bsnl Jagatpur Chenpur Road, Ahmedabad, Gujarat, India – 380081
- IndustryLife Sciences, Biotechnology
To see the full contact details of Inquest Biopharm Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Inquest Biopharm is professional, scientific and technical. In detail, this covers architecture, engineering activities, technical testing and analysis activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M4 | Architecture, engineering activities, technical testing and analysis activities |
To see the full business activity and turnover split of Inquest Biopharm Private Limited, buy the company report.
Financials of Inquest Biopharm Private Limited
FY 2025 filings availableInquest Biopharm Private Limited reported revenue of ₹77.08 Lakh (down 33% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 33% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 4%. EBITDA fell 27% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.9 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.43 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.4% | ||||
| Net Profit Margin | 9.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Inquest Biopharm Private Limited, buy the company report.
Board of directors of Inquest Biopharm Private Limited
Inquest Biopharm has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kapil Ashvinbhai Pandya | Director | 14 Sep 2017 | 9 Years 2 Months | Current |
| Minakshi Kapil Pandya | Director | 14 Sep 2017 | 9 Years 2 Months | Current |
Legal cases
No court or tribunal cases involving Inquest Biopharm Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Inquest Biopharm Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Inquest Biopharm has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAECI6298M1ZZ | Gujarat | Active | 25 Oct 2017 |
To see the full GST registrations and return filing status of Inquest Biopharm Private Limited, buy the company report.
Recent activity
Inquest Biopharm Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Kapil Ashvinbhai Pandya was appointed as Director on 14 Sep 2017.
Frequently asked questions
Inquest Biopharm is an active private limited company based in Ahmedabad, Gujarat, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 14 September 2017 (9+ years old) and is registered under CIN U73100GJ2017PTC099096.
Inquest Biopharm has 2 current directors:
- Kapil Ashvinbhai Pandya - Director
- Minakshi Kapil Pandya - Director
The latest financial statements of Inquest Biopharm on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Inquest Biopharm is 24AAECI6298M1ZZ, registered in Gujarat.
The CIN (Corporate Identification Number) of Inquest Biopharm is U73100GJ2017PTC099096. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Inquest Biopharm was incorporated on 14 September 2017, making it 9+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Kapil Ashvinbhai Pandya was appointed as Director on 14 Sep 2017. Minakshi Kapil Pandya was appointed as Director on 14 Sep 2017.
Inquest Biopharm can be reached through the website inquestbp.com. Its registered office is in Ahmedabad, Gujarat, India.
The registered office of Inquest Biopharm is at E – 512 Ganesh Glory – 11, Near Bsnl Jagatpur Chenpur Road, Ahmedabad, Gujarat, India – 380081.
Inquest Biopharm operates in the life sciences industry, in the biotechnology segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
